| Christopher James Jankowski, | |
|
2705 E 17th St, Ammon, ID 83406-6601 | |
| (208) 346-7500 | |
| Not Available |
| Full Name | Christopher James Jankowski |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 2705 E 17th St, Ammon, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265114516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 56107 (Idaho) | Primary |
| Entity Name | Pearl Health Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447426465 PECOS PAC ID: 0840356077 Enrollment ID: O20090312000617 |
News Archive
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
Talecris Biotherapeutics Holdings Corp. today announced that Talecris and Grifols S.A. have each received a request for additional information and documentary material, often referred to as a "Second Request," from the U.S. Federal Trade Commission (FTC) in connection with their proposed merger.
Offering flu vaccines at elementary schools could expand vaccination rates and reduce costs, according to a new study reported in the scientific journal Vaccine by researchers from UC Davis Health System; the Monroe County, New York, Department of Public Health; University of Rochester Medical Center; and U.S. Centers for Disease Control and Prevention.
Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher James Jankowski, 2705 E 17th St, Ammon, ID 83406-6601 Ph: (208) 346-7500 | Christopher James Jankowski, 2705 E 17th St, Ammon, ID 83406-6601 Ph: (208) 346-7500 |
News Archive
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
Talecris Biotherapeutics Holdings Corp. today announced that Talecris and Grifols S.A. have each received a request for additional information and documentary material, often referred to as a "Second Request," from the U.S. Federal Trade Commission (FTC) in connection with their proposed merger.
Offering flu vaccines at elementary schools could expand vaccination rates and reduce costs, according to a new study reported in the scientific journal Vaccine by researchers from UC Davis Health System; the Monroe County, New York, Department of Public Health; University of Rochester Medical Center; and U.S. Centers for Disease Control and Prevention.
Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.
› Verified 3 days ago
Jayde Barnes, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2705 E 17th St, Ammon, ID 83406 Phone: 208-346-7500 Fax: 208-346-7501 | |
Melissa Phillips Fehrenbacker, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1499 Curlew Dr, Ammon, ID 83406 Phone: 208-227-3355 Fax: 208-529-6631 | |
Nicole Boyle, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2705 E 17th St, Ammon, ID 83406 Phone: 208-757-3973 | |
Michelle Norman, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2705 E 17th St, Ammon, ID 83406 Phone: 208-346-7501 | |
David Paul Adams, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1675 Curlew Dr, Ammon, ID 83406 Phone: 208-523-5319 Fax: 208-523-5627 | |
Miss Jacqueline Romrell, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3067 Eagle Dr, Ammon, ID 83406 Phone: 208-522-4600 Fax: 208-552-7521 |